Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors

BACKGROUND: Atypical teratoid/thabdoid tumor (AT/RT) remains a difficult-to-treat tumor with a 5-year overall survival rate of 15%–45%. Proteasome inhibition has recently been opened as an avenue for cancer treatment with the FDA approval of bortezomib (BTZ) in 2003 and carfilzomib (CFZ) in 2012. Th...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neurooncol Adv
Prif Awduron: Morin, Andrew, Soane, Caroline, Pierce, Angela, Sanford, Bridget, Jones, Kenneth L, Crespo, Michele, Zahedi, Shadi, Vibhakar, Rajeev, Mulcahy Levy, Jean M
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2020
Pynciau:
Basic and Translational Investigations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7236404/
https://ncbi.nlm.nih.gov/pubmed/32642704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa051
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg